{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ffv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10006","date":"2024-01-17T22:31:33.996Z","role":"Publisher"},{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10006","date":"2023-12-06T07:00:00.000Z","role":"Approver"}],"curationReasons":{"id":"cg:NewCuration"},"evidence":[{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:254aff80-76c1-4ab7-8c54-96711451be89","type":"EvidenceLine","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"cggv:29333930-c058-4fa2-9ad2-326b3c15edf1","type":"FunctionalAlteration","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had significantly reduced translation rate and proliferation rates in homozygous cells compared to het. and wild-type cells","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30409806","type":"dc:BibliographicResource","dc:abstract":"We estimated the genome-wide contribution of recessive coding variation in 6040 families from the Deciphering Developmental Disorders study. The proportion of cases attributable to recessive coding variants was 3.6% in patients of European ancestry, compared with 50% explained by de novo coding mutations. It was higher (31%) in patients with Pakistani ancestry, owing to elevated autozygosity. Half of this recessive burden is attributable to known genes. We identified two genes not previously associated with recessive developmental disorders, ","dc:creator":"Martin HC","dc:date":"2018","dc:title":"Quantifying the contribution of recessive coding variation to developmental disorders."},"rdfs:label":"CRISPR-Cas9 iPSC line with p.Phe232Val variant"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0,"dc:description":"Not scored as experimental evidence since this data was used as variant-level functional evidence"}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ff17da1e-aadc-4891-aada-5273ccf80206_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ff17da1e-aadc-4891-aada-5273ccf80206","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003754.3(EIF3F):c.694T>G (p.Phe232Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5870630"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000365","obo:HP_0000708","obo:HP_0007359","obo:HP_0001770","obo:HP_0001263"],"sex":"Male","variant":{"id":"cggv:23c06888-c40b-45e9-8a96-09c75e21b5db_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30409806"},"rdfs:label":"265927"},{"id":"cggv:23c06888-c40b-45e9-8a96-09c75e21b5db","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:23c06888-c40b-45e9-8a96-09c75e21b5db_variant_evidence_item"},{"id":"cggv:23c06888-c40b-45e9-8a96-09c75e21b5db_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:63327e6b-439c-41b5-af3f-176a716ea6bf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:63327e6b-439c-41b5-af3f-176a716ea6bf","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":48,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001263","obo:HP_0001249","obo:HP_0000708","obo:HP_0001250"],"sex":"Male","variant":{"id":"cggv:af09e974-9247-4b82-a301-89733cfcad5c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30409806"},"rdfs:label":"292687"},{"id":"cggv:af09e974-9247-4b82-a301-89733cfcad5c","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:af09e974-9247-4b82-a301-89733cfcad5c_variant_evidence_item"},{"id":"cggv:af09e974-9247-4b82-a301-89733cfcad5c_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:b4cf85f0-6ee0-42e5-a81b-9409e0790e81_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b4cf85f0-6ee0-42e5-a81b-9409e0790e81","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001263","obo:HP_0001999","obo:HP_0040019","obo:HP_0000750","obo:HP_0001252","obo:HP_0001249","obo:HP_0001270"],"sex":"Female","variant":{"id":"cggv:98ac056e-538a-4658-90a3-6a17623de136_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33736665","type":"dc:BibliographicResource","dc:abstract":"An identical homozygous missense variant in EIF3F, identified through a large-scale genome-wide sequencing approach, was reported as causative in nine individuals with a neurodevelopmental disorder, characterized by variable intellectual disability, epilepsy, behavioral problems and sensorineural hearing-loss. To refine the phenotypic and molecular spectrum of EIF3F-related neurodevelopmental disorder, we examined independent patients.","dc:creator":"HÃ¼ffmeier U","dc:date":"2021","dc:title":"EIF3F-related neurodevelopmental disorder: refining the phenotypic and expanding the molecular spectrum."}},"rdfs:label":"pedigree10"},{"id":"cggv:98ac056e-538a-4658-90a3-6a17623de136","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:98ac056e-538a-4658-90a3-6a17623de136_variant_evidence_item"},{"id":"cggv:98ac056e-538a-4658-90a3-6a17623de136_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8b1aafc0-70c7-4d15-8cd5-b611c43eb544_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8b1aafc0-70c7-4d15-8cd5-b611c43eb544","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":20,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001249","obo:HP_0001263","obo:HP_0000365","obo:HP_0000708","obo:HP_0100797"],"sex":"Male","variant":{"id":"cggv:f438eb13-9556-4ac1-aac2-4d791bbed543_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30409806"},"rdfs:label":"277267"},{"id":"cggv:f438eb13-9556-4ac1-aac2-4d791bbed543","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:f438eb13-9556-4ac1-aac2-4d791bbed543_variant_evidence_item"},{"id":"cggv:f438eb13-9556-4ac1-aac2-4d791bbed543_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3c115939-9d8c-45da-9581-9008c265e4a0_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3c115939-9d8c-45da-9581-9008c265e4a0","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001263","obo:HP_0001249","obo:HP_0000750","obo:HP_0000708","obo:HP_0001270","obo:HP_0001999","obo:HP_0000365"],"sex":"Female","variant":{"id":"cggv:662aa26e-964b-42aa-9aff-fdce0588e1c2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33736665"},"rdfs:label":"pedigree1"},{"id":"cggv:662aa26e-964b-42aa-9aff-fdce0588e1c2","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:662aa26e-964b-42aa-9aff-fdce0588e1c2_variant_evidence_item"},{"id":"cggv:662aa26e-964b-42aa-9aff-fdce0588e1c2_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:60052dfa-511b-4555-9891-27661ef00020_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:60052dfa-511b-4555-9891-27661ef00020","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0001270","obo:HP_0000750","obo:HP_0001263","obo:HP_0001252","obo:HP_0001249","obo:HP_0000365","obo:HP_0001999","obo:HP_0001276"],"sex":"Male","variant":{"id":"cggv:06262dfd-5071-4bb9-9677-8ea49b150cfb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33736665"},"rdfs:label":"pedigree15"},{"id":"cggv:06262dfd-5071-4bb9-9677-8ea49b150cfb","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:06262dfd-5071-4bb9-9677-8ea49b150cfb_variant_evidence_item"},{"id":"cggv:06262dfd-5071-4bb9-9677-8ea49b150cfb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5f1da883-8909-4892-9439-4217584ce8c3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5f1da883-8909-4892-9439-4217584ce8c3","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":34,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001263","obo:HP_0001270","obo:HP_0000545","obo:HP_0001249","obo:HP_0000750","obo:HP_0001999","obo:HP_0000365","obo:HP_0000709","obo:HP_0000708","obo:HP_0001252"],"sex":"Female","variant":{"id":"cggv:c2bca2cb-f061-40c2-ba13-7cce9ed4dbaf_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33736665"},"rdfs:label":"pedigree14"},{"id":"cggv:c2bca2cb-f061-40c2-ba13-7cce9ed4dbaf","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c2bca2cb-f061-40c2-ba13-7cce9ed4dbaf_variant_evidence_item"},{"id":"cggv:c2bca2cb-f061-40c2-ba13-7cce9ed4dbaf_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:5c9daf8c-6af0-4125-8fe2-35aea0017e5e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:5c9daf8c-6af0-4125-8fe2-35aea0017e5e","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":27,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001249","obo:HP_0000708","obo:HP_0001263","obo:HP_0001298","obo:HP_0001252","obo:HP_0000750"],"sex":"Female","variant":{"id":"cggv:ca25b335-a3cc-4ded-89aa-496da9ed60eb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33736665"},"rdfs:label":"pedigree4"},{"id":"cggv:ca25b335-a3cc-4ded-89aa-496da9ed60eb","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ca25b335-a3cc-4ded-89aa-496da9ed60eb_variant_evidence_item"},{"id":"cggv:ca25b335-a3cc-4ded-89aa-496da9ed60eb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:53a90e99-050a-4a63-b53b-2eec5b17d63c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:53a90e99-050a-4a63-b53b-2eec5b17d63c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001270","obo:HP_0001249","obo:HP_0000750","obo:HP_0001263","obo:HP_0001250"],"sex":"Female","variant":{"id":"cggv:2c2f249b-6c91-4931-9c17-97943a8ce457_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30409806"},"rdfs:label":"269196"},{"id":"cggv:2c2f249b-6c91-4931-9c17-97943a8ce457","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:2c2f249b-6c91-4931-9c17-97943a8ce457_variant_evidence_item"},{"id":"cggv:2c2f249b-6c91-4931-9c17-97943a8ce457_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:47f85a92-0d4d-4e81-b643-371517ca8ac6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:47f85a92-0d4d-4e81-b643-371517ca8ac6","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001270","obo:HP_0000486","obo:HP_0000750","obo:HP_0000708","obo:HP_0002121","obo:HP_0001263","obo:HP_0001249","obo:HP_0000365"],"sex":"Female","variant":{"id":"cggv:d95c935f-672a-4da4-87ec-71da57eb9c70_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30409806"},"rdfs:label":"283926"},{"id":"cggv:d95c935f-672a-4da4-87ec-71da57eb9c70","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d95c935f-672a-4da4-87ec-71da57eb9c70_variant_evidence_item"},{"id":"cggv:d95c935f-672a-4da4-87ec-71da57eb9c70_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:dd7009a3-03cc-40e9-90b6-d09fe645cf36_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:dd7009a3-03cc-40e9-90b6-d09fe645cf36","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":[{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},{"id":"cggv:c0a08066-39a3-41bc-91d2-80c8627579ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003754.3(EIF3F):c.861dup (p.Gln288AlafsTer14)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2580084025"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001270","obo:HP_0000365","obo:HP_0001249","obo:HP_0000750","obo:HP_0001999","obo:HP_0000486","obo:HP_0007359","obo:HP_0000639","obo:HP_0001263"],"sex":"Female","variant":[{"id":"cggv:a3254145-59e3-4dab-9084-0d17f43a622c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c0a08066-39a3-41bc-91d2-80c8627579ae"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33736665"},{"id":"cggv:4579d468-0f5a-462c-a733-c5ac4256718a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:67c91fec-99db-418f-95f0-fd73f280cedb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/33736665"}],"rdfs:label":"pedigree3"},{"id":"cggv:4579d468-0f5a-462c-a733-c5ac4256718a","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:4579d468-0f5a-462c-a733-c5ac4256718a_variant_evidence_item"},{"id":"cggv:4579d468-0f5a-462c-a733-c5ac4256718a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"CRISPR-Cas9 derived iPSC lines with the p.Phe232Val variant had ~27% lower EIF3F protein levels in homozygous cells compared to het. and wild-type cells"}],"strengthScore":0.5},{"id":"cggv:a3254145-59e3-4dab-9084-0d17f43a622c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:a3254145-59e3-4dab-9084-0d17f43a622c_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":7581,"specifiedBy":"GeneValidityCriteria9","strengthScore":12,"subject":{"id":"cggv:387dadb1-1eb6-4681-940e-8ef21eae4fff","type":"GeneValidityProposition","disease":"obo:MONDO_0000508","gene":"hgnc:3275","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"*EIF3F* was first reported in relation to autosomal recessive syndromic intellectual disability in 2018 (Martin et al., PMID: 30409806). *EIF3F* encodes an essential subunit of eIF3, the largest eukaryotic translation initiation factor, which plays a role in cell proliferation and growth, cell cycle control, differentiation, and apoptosis. At least 31 patients from 24 families have been reported with biallelic *EIF3F* variants; 30 of these patients were homozygous for the same p.Phe232Val missense variant, and 1 patient was compound heterozygous for the p.Phe232Val missense variant and a frameshift variant (PMIDs: 30409806, 33736665). Haplotype analyses suggested that p.Phe232Val is a founder variant (PMID: 33736665). The p.Phe232Val variant has a frequency of 0.16% in non-Finnish Europeans, and no homozygotes are observed in gnomAD (v4.0.0). The mechanism of pathogenicity appears to be loss of function. Affected individuals present with global developmental delay, motor and speech delays, and intellectual disability; variable features include hearing loss, dysmorphic facial features, abnormal behaviors, hypo- or hypertonia, ophthalmological abnormalities, and epilepsy (PMIDs: 30409806, 33736665). \n\nInduced pluripotent stem cells (iPSC) homozygous for the p.Phe232Val missense variant had ~27% lower EIF3F protein levels, and significantly reduced translation and proliferation rates compared to heterozygous and wild-type cells (PMID: 30409806). \n\nIn summary, there is definitive evidence supporting the relationship between *EIF3F* and autosomal recessive syndromic intellectual disability. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on December 6, 2023 (SOP Version 9).\n","dc:isVersionOf":{"id":"cggv:d0f623e7-ea96-461a-a348-7aa5a7a1d7ff"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}